OBJECTIVES:: To assess the economic and humanistic burden of psoriatic arthritis (PsA) among psoriasis (PsO) patients in Brazil, and draw descriptive analyses between the two cohorts. METHODS:: This analysis used data from the GfK Disease Atlas multinational real-world evidence program. The sample included dermatologists (n=50) and their systemic therapy eligible PsO patients (n=497); data was captured into a retrospective database through surveys. RESULTS:: Among PsO patients, 18% (n=90) had PsA; of which, 52% were male. Patients with PsA were older than those without PsA (53.7 vs. 43.6 years), and had a greater disease duration (11.9 vs. 6.6 years). Patients with PsA reported a higher number of exacerbations in the last 12 months; 33% (n=30) reported currently exacerbating, compared to 14% (n=16) of those without PsA. The most bothersome symptom for patients with PsA was joint pain (27% vs. 0% for non-PsA patients), while those without PsA reported scaling as the most bothersome (30% vs. 27% for PsA patients). Nearly 20% of PsO patients (n=88) reported suffering from anxiety or depression, while nearly 30% (n=25) of PsA patients did. The overall SF-12 physical and mental health composite scores for patients with PsA were 43.7 and 41.9 respectively, versus 52.2 and 46.8 respectively for those without. Work productivity loss was 31.9% for patients with PsA, versus 19.5% for those without. Absenteeism and presenteeism were 10% and 25.6% respectively for patients with PsA, versus 5.1% and 16.3% respectively for those without. The number of PsO consultations with a dermatologist was higher for patients with PsA, specifically 16% (n=14) versus 8% (n=31) for those without PsA. Further, 36% (n=32) of PsA patients sought care from a rheumatologist, while only 3% (n=11) of patients without PsA did. CONCLUSIONS:: Results from this real world survey showed that the economic and humanistic burden in psoriasis patients with concomitant PsA is substantial.